Liver Cirrhosis, Portal Vein Thrombosis
Conditions
Keywords
anticoagulation, Zelen-designed randomized controlled trial
Brief summary
To determine the effect and safety of anticoagulation after endoscopic therapy in cirrhotic patients with portal vein thrombosis and to explore whether it can decrease the short-term rebleeding rate.
Detailed description
The treatment of cirrhotic patients with PVT (portal vein thrombosis) is clearly recommended in guideline now. Several published studies has confirm the effect and safety of anticoagulation therapy in cirrhotic patients with PVT.The present studies are most observation studies with small sample size and low quality.We need more high-quality research such as randomized controlled trials. This is a Zelen-designed randomized controlled trial. Patients will randomly enter into two groups:the anticoagulation group or the control group and then we will make sure wether their are fond of the group and make decision by themselves. The recanalization rate and complications will be analyzed
Interventions
Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
Sponsors
Shanghai Zhongshan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18-70 years old; * A clinical, radiological or histologic diagnosis of Liver cirrhosis and portal hypertension; * Diagnosed of Portal vein thrombosis; * Capable of understanding the purpose and risks of the study and informed consent to participate in the study; * Have undergone endoscopy to prevent variceal rebleeding.
Exclusion criteria
* Age \<18 or \>70 years; * Portal vein thrombosis diagnosed before 6 months; * Patients with signs of acute PVT such as fever，abdominal pain or intestinal obstruction，who should be treated immediately; * Pregnant or nursing; * Hepatocellular carcinoma; * Severe cardiopulmonary diseases or concomitant renal insufficiency; * cavernous transformation of the portal vein; * Contradictions to endoscopy; * Contradictions to anticoagulation,such as:allergy to LMWH or warfarin, severe uncontrolled hypertension, history of hemorrhagic cerebral vascular accident, recent peptic ulcer disease, bacterial endocarditis, ulcerative colitis，sustained platelet count \< 50 x103/uL); * Taking immunosuppressive agent; * Coagulation disorders other than the liver disease related; * Variceal bleeding failed to control.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recanalization rate of PVT | 8 weeks | Patients will receive Doppler ultrasound before enrolled and after followed up for 8 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rebleeding rate | 8 weeks | The investigators observe the variceal rebleeding events during 8 weeks. |
| Incidence rate of complications | 8 weeks | The investigators observe any severe adverse events caused by anticoagulation therapy or the progress of thrombosis. |
Countries
China
Contacts
Primary ContactShiyao Chen, Professor
Outcome results
None listed